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Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive loss
of cognition. Over 35 million individuals currently have AD worldwide. Unfortunately, current therapies are
limited to very modest symptomatic relief. The brains of AD patients are characterized by the deposition of
amyloid-β and hyperphosphorylated forms of tau protein. AD brains also show neurodegeneration and high
levels of oxidative stress and inflammation. The phytocannabinoid cannabidiol (CBD) possesses
neuroprotective, antioxidant and anti-inflammatory properties and reduces amyloid-β production and tau
hyperphosphorylation in vitro. CBD has also been shown to be effective in vivo making the phytocannabinoid
an interesting candidate for novel therapeutic interventions in AD, especially as it lacks psychoactive or
cognition-impairing properties. CBD treatment would be in line with preventative, multimodal drug strategies
targeting a combination of pathological symptoms, which might be ideal for AD therapy. Thus, this review will
present a brief introduction to AD biology and current treatment options before outlining comprehensively
CBD biology and pharmacology, followed by in-vitro and in-vivo evidence for the therapeutic potential of
CBD. We will also discuss the role of the endocannabinioid system in AD before commenting on the potential
future of CBD for AD therapy (including safety aspects).
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Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterised by
progressive loss of cognition. Over 35 million people are currently diagnosed with AD worldwide.
Unfortunately, current therapies are limited to very modest symptomatic relief. Brains of AD patients
are characterised by deposition of amyloid-β (Aβ) and hyperphosphorylated forms of tau protein. AD
brains also exhibit neurodegeneration and show high levels of oxidative stress and inflammation. The
phytocannabinoid cannabidiol (CBD) possesses neuroprotective, anti-oxidant, and anti-inflammatory
properties and reduces Aβ production and tau hyperphosphorylation in vitro. CBD has also been shown
to be effective in vivo making the phytocannabinoid an interesting candidate for novel therapeutic
interventions in AD, especially as it lacks psychoactive or cognition-impairing properties. CBD
treatment would be in line with preventative, multimodal drug strategies targeting a combination of
pathological symptoms, which might be ideal for AD therapy. Thus, this review will give a brief
introduction to AD biology and current treatment options before outlining comprehensively CBD
biology and pharmacology followed by in vitro and in vivo evidence for CBD’s therapeurtic potential.
We will also discuss the role of the endocannabinioid system in AD before commenting on the
potential future of CBD for AD therapy (including safety aspects).

Keywords: Alzheimer’s disease, dementia, cannabinoids, cannabidiol, endocannabinoid system,
cannabinoid receptor, therapy, cognition, learning and memory, mouse model
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Abbreviations
2-AG: 2-arachidonylglycerol (endocannabinoid)
2-LG: 2-linoleoylglycerol
5-HT: 5-hydroxytryptamine / serotonin
5-HT1A: serotonergic 5-hydroxytryptamine 1A receptor
A2A: adenosine 2A receptor
Aβ: beta-amyloid protein; majority of Aβ is 40 residues in length (Aβ40), whereas approximately 10%
form the 42 residue-length variant (Aβ42)
ABHD6: Serine hydrolase alpha/beta-hydrolase domain-containing 6
ACEA: arachidonyl-20-chloroethylamide (CB1 agonist)
AICD: amyloid precursor protein intracellular domain
AEA: anandamide (also called Ν-arachidonoylethanolamine)
AMPA: 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid
APP: amyloid precursor protein
ATP: adenosine triphosphate
BDNF: brain-derived neurotrophic factor
Ca2+: calcium ions
CB1: cannabinoid receptor 1
CB2: cannabinoid receptor 2
CBD: cannabidiol (phytocannabinoid)
CGS-21680: A2A receptor agonist
CNS: central nervous system
COX-2: cyclooxygenase 2
CP 55,940: synthetic cannabinoid, full agonist of CB1 and CB2 (>40 more potent than THC)
CSF: cerebrospinal fluid
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DAGL-α/β: diacylglycerol lipases α/β
Dronabinol: pharmaceutical formulation of THC
DNA: deoxyribonucleic acid
18

FDG: 18F-fluoro-deoxyglucose

FAAH: fatty acid amide hydrolase
GABA: γ-aminobutyric acid
GFAP: glial fibrillary acidic protein
GPR18 / GPR55 / GPR118: G-protein coupled receptors 18, 55, and 119
GSK3-β: glycogen synthase kinase 3 β
GW9662: peroxisome proliferator-activated receptor γ antagonist
HU-308: synthetic cananbiniod; selective CB2 agonist
Iba1: ionised calcium binding adaptor molecule 1 (i.e. a microglia/macrophage-specific calciumbinding protein)
INF-γ: interferon γ
i.p.: intraperitoneal
i.c.v.: intracerebroventricular
IL: interleukin
JWH-133: synthetic cannabinoid selective for CB2
MDA7: 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine - a novel highly
selective CB2 agonist
MAGL: monoacylglycerol lipase
Nabilone: synthetic cannabinoid mimicking the effects of THC
NAPE-PLD: N-acyl phosphatidylethanolamine-selective phospholipase D
NMDA: N-methyl-D-aspartate
NF-ĸB: transcription factor nuclear factor ĸB
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NFT: neurofibrillarly tangle
NO: nitric oxide
iNOS: inducible nitric oxide synthase
p-GSK3β: phosphorylated glycogen synthase kinase 3 β
p38 MAP kinase: p38 mitogen-associated protein kinase
PEA: palmitoylethanolamide
PET: positron emission tomography
PND: Postnatal day
PPARγ: peroxisome proliferator-activated receptor γ
PS1: presenilin 1
PS2: presenlin 2
ROS: reactive oxygen species
Sativex®: mixture of a THC botanical extract (containing 67.1% THC, 0.3% CBD, 0.9% cannabigerol,
0.9% cannabichromene, and 1.9% other phytocannabinoids) and a CBD botanical extract (containing
64.8% CBD, 2.3% THC, 1.1% cannabigerol, 3.0% cannabichromene, and 1.5% other
phytocannabinoids), developed/produced by GW Pharmaceuticals Ltd (Cambridge, UK) in a 1:1
proportion
SAPK/JNK: stress-activated protein kinase/c-Jun NH(2)-terminal kinase
SR141716: CB1 antagonist
SR144528: CB2 antagonist
SOD1/2: superoxide dismutase 1/2
THC: Δ9-tetrahydrocannabinol (phytocannabinoid)
TNF-α: tumor necrosis factor-alpha
HU-210: synthetic cannabinoid selective for CB1 (100-800 times more potent than THC)
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VR1: vanilloid receptor type 1; also known as the transient receptor potential cation channel subfamily
V member 1 (TRPV1)
VR2: vanilloid receptor type 2
WIN 55,212-2: synthetic cannabinoid with mixed CB1/CB2 agonism (similar to THC)
ZM241,385: A2A receptor antagonist
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Main Text
1. Alzheimer’s disease
As the world’s population ages and life expectancy increases, many individuals are faced with an
increased risk of developing dementia. Dementia is the severe loss of cognitive abilities that is not part
of the normal ageing process and currently, over 46 million people globally are living with dementia
(World Alzheimer Report 2015; (Ferri et al., 2005)). The most prominent form of dementia is
Alzheimer’s disease (AD), which is predicted to affect 1 in 85 people globally by the year 2050. AD is
categorised by three progressive clinical stages: mild, moderate and severe (Zandi et al., 2002). The
mild stage is characterised by short-term memory loss, subtle difficulties in learning and
communication as well as spatial disorientation. During the moderate stage, memory decline (e.g.
noticeable lapses in short-term memory and loss of reading and writing ability) begins to affect
everyday tasks resulting in increased frustration and loss of emotional control. In the severe stage, AD
patients face a universal disruption of cognitive abilities including severely impaired learning and
speech, inability to recognise familiar people and loss of control over bodily functions. Eventually,
individuals are left in a weakened physical state where they are prone to other illnesses (e.g.
infections).

1.1 Biology of Alzheimer’s disease
AD is characterised as either sporadic (late-onset) or familial (early onset, autosomal dominant).
Sporadic AD is the most common and least understood form of AD, accounting for up to 95% of
reported AD cases (Gotz and Ittner, 2008). The age of onset for sporadic AD is usually around 65
years. The cause of sporadic AD remains to be elucidated, but is believed to result from a complex
interaction of various environmental risk factors and multiple susceptibility genes (Kamboh, 2004). A
great deal of information has been gained from the analysis of genetic risk factors. APOE genotype is
by far the most robust predictor of AD risk with the ε4 allele affording increased risk and the ε2 allele
7

affording protection as compared to the most common ε3 allele (Corder et al., 1993). Genome-wide
association studies (GWAS) studies have confirmed the importance of APOE in AD risk and also
identified several additional genetic risk factors, many of which are, like APOE, related to lipid
homeostasis (e.g. GAB2) (Belbin et al., 2011).
Familial AD is autosomal dominant and accounts for <10% of cases, with an earlier age of onset than
the sporadic form, and often occurring at 40-50 years of age. Familial AD is linked to mutations in the
amyloid precursor protein gene (APP) or in genes encoding presenilin 1 (PS1) and presenilin 2 (PS2).
Mutations in PS1 or PS2 cause the most common and aggressive forms of familial AD and are
responsible for the activity of γ-secretase, one of the enzymes responsible for the cleavage of APP into
β-amyloid peptides (Aβ). Aβ peptides are found in human brains and have an important damaging
pathological function in AD. However, they are also involved in several other processes, including the
regulation of cholesterol transport, antioxidant, and anti-microbial properties (Baruch-Suchodolsky and
Fischer, 2009, Soscia et al., 2010, Umeda et al., 2010). They possess high turnover rates and are
associated with synaptic vesicle release, implying a role in neurotransmission (Marchesi, 2011).
APP is cleaved and processed by α-, β- and γ-secretases via two pathways, a non-amyloidogenic and an
amyloidogenic pathway. The non-amyloidogenic pathway accounts for the majority of APP processing
in the healthy brain whereby APP is cleaved by α-secretase to generate: 1) a soluble N-terminal
fragment (sAPPα), which has neuroprotective properties; 2) a C-terminal fragment (CTFα), that is
retained in the membrane and processed further by γ-secretase to yield an N-terminal fragment (p3);
and, 3) a membrane-bound C-terminal fragment, the APP intracellular domain (AICD), which regulates
gene transcription. A minority of APP is processed by the amyloidogenic pathway, leading to the
generation of Aβ: first, β-secretase cleaves APP resulting in soluble APP and a cell-membrane bound
fragment; second, γ-secretase cleaves this fragment further, producing Aβ and AICD. Importantly, the
majority of Aβ produced are 40 residues in length (Aβ40), whereas approximately 10% form the 42
residue-length variant (Aβ42). Aβ42 is the longer, more hydrophobic isoform that is more prone to fibril
8

formation, and therefore found predominantly in cerebral plaques. Mutations in APP or the genes for
the APP-processing enzymes presenilin 1 or presenilin 2 appear to influence the overproduction of
Aβ42. The excessive production of Aβ42 increases its aggregation in extracellular deposits that form
amyloid or senile plaques, one of the two distinct types of lesions observed post-mortem in brains of
AD patients.
The second pathological hallmark of AD is the intracellular accumulation and hyperphosphorylation of
microtubule-associated protein tau (MAPT), which leads to the formation of neurofibrillary tangles
(NFT). Tau is predominantly found in axons of neurons, where it promotes the assembly of
microtubules from tubulin, stabilises them, and supports microtubule-dependent axonal transport of
organelles and biomolecules. In the healthy brain, 2-3 amino acid residues on tau are phosphorylated,
whereas in AD, tau proteins are hyperphosphorylated (average of 9 phosphates per molecule), leading
to lowered tau affinity for microtubules, increased tau resistance to calcium-activated neutral proteases
and finally the aggregation and formation of NFTs (Lie et al., 2005). However, so far, no tau mutations
have been linked to AD (Andorfer et al., 2003, Wolfe, 2009, Armstrong, 2013).
The presence of elevated Aβ in the brain is strongly correlated with cognitive decline in patients
diagnosed with early dementia (Naslund et al., 2000) and this has been confirmed using transgenic AD
mouse models that routinely express mutant forms of APP and PS1 (Hsiao et al., 1996, Holcomb et al.,
1998). However, other preclinical data argue against a direct correlation of amyloid plaque load with
cognitive abilities in AD mouse models suggesting that that amyloid plaques might not be the cause of
AD but rather a consequence of pathologic changes in brain metabolism (Stumm et al., 2013). It has
been hypothesised that deposits of Aβ are responsible for causing and exacerbating tau
hyperphosphorylation and the generation of NFTs, as Aβ depositions have been found prior to any
signs of tau pathology (Gotz et al., 2001). Accumulation of tau and the associated NFTs induce
cognitive deficits, which correlate with neurodegeneration. Transgenic mouse models expressing tau
mutations demonstrate cognitive deficits and AD-relevant pathology (Barten et al., 2012). These
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processes eventually lead to neuronal death and ultimately dementia (amyloid cascade hypothesis). In
humans, extensive tau pathology is generally associated with later stages of AD, but changes in tau
biology could potentially also occur much earlier (Kuret et al., 2005). Some researchers argue that tau
pathology correlates best with AD progression (Gotz et al., 2008).
An additional hypothesis regarding the role of Aβ in AD suggests that resting microglia become
activated in response to the presence of Aβ and cluster at sites of amyloid deposition in the brain. This
initiates neuroinflammatory processes and the release of neurotoxic factors (e.g. pro-inflammatory
cytokines and reactive oxygen and nitrogen species) (Streit, 2004), resulting in the manifestation of
several characteristic AD-pathologies such as neurodegeneration, neuroinflammation, neurotoxicity
and

oxidative

damage

(amyloid

cascade-neuroinflammation

hypothesis).

On

one

side,

neuroinflammation could be a beneficial event, inducing an immune response to start the phagocytosis
of amyloid species in an attempt to limit the development of the disease. On the other side, prevailing
evidence suggests that neuroinflammation is a driving force in the acceleration of AD development as
it triggers the production of proinflammatory chemokines, cytokines, and neurotoxins by the activated
microglia and astrocytes in the brain. It should also be recognised that microglia exist in a spectrum of
functional phenotypes that may reflect helpful (e.g. A clearance) or harmful (e.g. over-production of
pro-inflammatory cytokines and free radicals) roles. Recently, approaches to selectively upregulate the
helpful functions of microglia have received increased attention (Perry et al., 2010, McGeer and
McGeer, 2015)

1.2 Treatment of Alzheimer’s disease
Given the looming burden of AD, pharmacological regimens that could delay or even prevent the onset
of AD would offer tremendous public health benefits. Based on the complex pathology of AD, a
preventative, multimodal drug approach targeting a combination of pathological AD events early in
disease development appears ideal. Unfortunately, current AD treatments only provide limited relief for
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cognitive and functional decline in the early stages of the disease and are ineffective against disease
progression (Zandi and Breitner, 2001, Benito et al., 2007, Marchalant et al., 2008, Karl et al., 2012).
Furthermore, these treatment options cause a range of adverse side effects (e.g. nausea, vomiting,
abdominal pain, headache, depression, and dizziness) (Benito et al., 2007, Micale et al., 2007,
Marchalant et al., 2008). Therefore, it is necessary to explore new therapeutic avenues. Importantly,
cannabinoids show anti-inflammatory, neuroprotective and anti-oxidant properties and have
immunosuppressive effects. More recently, cannabinoids have also been found to possess properties
that may reduce Aβ and tau pathology. Thus, cannabinoid-related intervention strategies may have
therapeutic properties in AD. The phytocannabinoid cannabidiol (CBD) is of particular interest as it
lacks the psychoactive and cognition-impairing properties of other cannabinoids. What is currently
known about CBD’s pharmacological properties and its potential role in AD therapy will be outlined in
the following sections.

2. Cannabidiol (CBD)
The phytocannabinoid CBD was first isolated from cannabis sativa in 1940 (Adams, 1940) and its
structure was elucidated in the 60’s (Mechoulam and Gaoni, 1965). CBD has very low toxicity. The
LD50 after intravenous administration to the rhesus monkey is 212 mg/kg whereas the oral LD50 could
not be established, probably due to the fact that CBD is barely absorbed systemically after oral
administration (i.e. oral bioavailability ranges between 13% and 19%) (Mechoulam et al., 2002). If
injected, CBD is rapidly distributed and easily passes the blood–brain barrier due to its lipophilicity,
which in turn provides CBD a prolonged elimination (Grotenhermen 2003). A high volume of
distribution (~32 l/kg) has been estimated, with rapid distribution not only in the brain but also adipose
tissue and other organs (Devinsky et al., 2014). Preferential distribution to fat raises the possibility of
accumulation of CBD depots in chronic administration schemes, especially in patients with high
adiposity. The metabolism of CBD shows biotransformation routes typically observed for
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phytocannabinoids [but species differences must be considered when assessing preclinical research
data, see (Bergamaschi et al., 2011)]. CBD undergoes multiple hydroxylations, oxidations to carboxylic
acids, β-oxidation, conjugation, and epoxidation (Harvey et al., 1991). Eventually, CBD is
preferentially excreted in urine, both in the free state and as its glucuronide, with a half-life of 9 h
[reviewed in (Iuvone et al., 2009)].
CBD pharmacological properties range from anti-convulsive, anti-anxiety, and anti-psychotic (Zuardi
et al., 1991, Zuardi et al., 1995, Leweke et al., 2000, Schneider et al., 2002) to anti-nausea, antiinflammatory, and anti-rheumatoid arthritic [outlined more comprehensively in (Pertwee, 2008, Russo,
2011)]. Importantly, CBD is a multi-target drug that can interact with many signaling systems
including the endocannabinoid system (outlined in more detail in section 2.2).

2.1 Brief introduction to the endocannabinoid system
The endocannabinoid system (ECS) is an intercellular signalling system comprised of G-protein
coupled cannabinoid receptors 1 (CB1) and 2 (CB2) as well as more recently discovered receptors (e.g.
N-arachidonyl glycine receptor or G-protein coupled receptor 18: GPR18); endogenous ligands, the
best characterised ones being the arachidonic acid derivatives Ν-arachidonoylethanolamine (also called
anandamide: AEA) and 2-arachidonoylglycerol (2-AG) and their homologues; and metabolic enzymes
(for overview see Table 1). The enzymes responsible for the biosynthesis of AEA require complete
characterisation but a N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) has been
implicated in the process as has diacylglycerol lipase- (DAGL-) for 2-AG. Metabolism of
anandamide and 2-AG require fatty amide acid hydrolase (FAAH) and monoacylglycerol lipase
(MAGL) respectively (Piomelli, 2003, Howlett et al., 2011). The ECS is involved in a variety of
physiological processes including appetite, pain sensation, mood, and cognition. There are two main
groups of cannabinoids that interact with the receptors of the ECS, namely the endogenous ligands (i.e.
2-AG and AEA) and exogenous cannabinoids. Exogenous cannabinoids include various
12

phytocannabinoids

derived

from

the

marijuana

plant,

Cannabis

sativa,

including

Δ9-

tetrahydrocannabinol (THC), the main psychoactive and cognition-impairing component, CBD, as well
as synthetic cannabinoids (i.e. cannabimimetics such as CP 55,940 and WIN 55,212-2) (Tanasescu and
Constantinescu, 2010) (for overview see Table 1).
CB1 receptors are highly expressed throughout the brain by many different classes of neurons and also
at lower levels by glial cells and many peripheral cell types (Pertwee, 2008). These receptors are found
in abundance in the basal ganglia, cerebellum, and more importantly the hippocampus,
parahippocampal and entorhinal cortices, suggesting an involvement of CB1 in learning and memory.
CB1 has also been implicated in cannabinoid-mediated modulation of immune functions (Cabral et al.,
2008). CB2 receptors are predominantly found on a variety of immune cells including B lymphocytes,
natural killer cells, monocytes/macrophages, and T cells suggesting a role in immunomodulation.
Importantly, CB2 is also densely expressed on activated microglia cells, which suggests a possible role
in mediating neuroinflammatory responses in the CNS. Stimulation of CB2 receptors in microglia not
only drives the proliferation and migration of microglia, but can also block their differentiation into a
neurotoxic phenotype (Stella, 2010).
Radioligand binding studies into the developmental pattern (neonatally until 32 months of age) of
cannabinoid receptors in the rat brain using the full CB1 and CB2 agonist CP 55,904 revealed that
cannabinoid receptor binding capacity increases progressively from birth to postnatal day (PND) 60 in
whole brain preparations whereas no further changes in binding are detected in adulthood and
throughout the normal aging process (Belue et al., 1995). Interestingly, and in line with emerging
evidence suggesting that Aβ depositions in AD brain are the result of impaired clearance, is the fact
that activation of CB1/CB2 by 2-AG as well as the suppression of the endocannabinoid-degrading
enzyme MGL (but not FAAH or ABHD6) elevates Aβ clearance across the blood-brain barrier
(Bachmeier et al., 2013).
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2.2 CBD pharmacology
CBD effects on the endocannabiniod system
The pharmacokinetic plasma pattern of CBD resembles that of THC, as does its metabolic pattern
(Grotenhermen, 2003). CBD has been found to have very low displacement activities at CB1 and CB2
receptors compared to other cannabinoids such as THC and WIN 55,212-2 (Thomas et al., 1998).
Another study in the same year confirmed that CBD has a very low affinity (micromolar range) for CB1
as well as CB2 receptors. More importantly, that work suggested that CBD develops antagonistic-like
properties against the synthetic cannabinoid, CP 55,940, which is a full and highly potent agonist of
CB1 and CB2 receptors, and that CBD has no agonistic activity of cannabinoid receptors even at high
concentrations (Petitet et al., 1998). These findings were in line with earlier reports showing that CBD
can reverse behavioural effects induced by THC (Karniol et al., 1974, Zuardi et al., 1981) although the
study by Petitet and coworkers found no blockade of CP 55,940-induced hypothermia in mice by CBD.
Interestingly, another study found that CBD antagonises (or inversely agonises) not only CP 55,940 but
also WIN 55,212-2. But because CBD produced this antagonism at concentrations well below those at
which it binds to cannabinoid receptors, the authors concluded that CBD acts at prejunctional sites that
are unlikely to be CB1 or CB2 receptors (Pertwee et al., 2002). In a follow-up study, CBD displayed
inverse agonism at human CB2 receptors and was a high potency antagonist (non-competitive) of
cannabinoid receptor agonists in mouse brains as well as in membranes from CHO cells transfected
with human CB2 (Thomas et al., 2007). CBD induced inverse agonism at CB2 receptors at
concentrations well below those at which it displaces CP 55,940. This characteristic of CBD may
contribute to its anti-inflammatory properties, as there is evidence that CB2 inverse agonism can inhibit
immune cell migration (Lunn et al., 2006). In line with this, CBD is a potent inhibitor of evoked
migration both of murine microglial cells and macrophages and of human neutrophils [reviewed in
(Pertwee, 2008)]. In addition, CBD appears to be an antagonist on GPR55 (Ryberg et al., 2007) and on
GPR18 (McHugh et al., 2010) receptors and activates the putative abnormal CBD receptor (Pertwee,
14

2005, 2008). Bisogno and coworkers discovered that CBD also interacts with vanilloid receptor type 1
(VR1), the receptor for capsaicin (Bisogno et al., 2001), as it stimulated VR1 with a maximal effect
similar in efficacy to that of capsaicin suggesting that VR1 may mediate some of the pharmacological
effects of CBD (VR1) (Bisogno et al., 2001). Finally, there is limited evidence that suggests CBD
might also activate VR2 (Izzo et al., 2009).
CBD also impacts brain endocannabinoid levels directly. An initial study reported interactions between
CBD and proteins that inactivate AEA (Bisogno et al., 2001). CBD inhibited AEA uptake and, to a
lesser extent, AEA hydrolysis. These findings suggested that increased levels of endogenous AEA due
to CBD-induced inhibition of AEA uptake and degradation (Watanabe et al., 1996) might mediate
some of the pharmacological effects of CBD. Supporting this idea is another study, which reported that
CBD blunts the expression and the activity of FAAH, the enzyme required for the degradation of both
AEA and 2-AG (de Filippis et al., 2008, Leweke et al., 2012).
CBD effects on other neurotransmitter systems and brain processes
The role of CBD in brain circuits other than the endocannabiniod system has also been evaluated. In
1998, CBD was found to protect against neurotoxicity mediated by glutamate receptors, i.e. N-methylD-aspartate (NMDA) receptors, 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid (AMPA)
receptors, and kainate receptors (Hampson et al., 1998). CBD has also been reported to exhibit a
modest agonistic affinity of human 5-HT1a receptors (Russo et al., 2005), where it inhibits 5-HT reuptake, and reduces overall 5-HT neurotransmission [reviewed in (Pertwee, 2004)]. In line with the
earlier statement that CBD has species-dependent properties, CBD discriminated between human and
rat orthologues of the 5-HT1A receptor (Russo et al., 2005). Furthermore, CBD enhanced adenosine
receptor A2A signalling via inhibition of cellular update of an adenosine transporter (Carrier et al.,
2006). This effect may be at least partially responsible for CBDs ability to decrease inflammation and
to be neuroprotective. Although not relevant for the in vivo effects (as CBD doses required were not
biologically relevant), CBD was reported to possess allosteric modulator properties for μ- and δ-opioid
15

receptors at very high concentrations (i.e. dissociation rate induced by naloxone and naltrindole at
receptors was accelerated by 100 µm CBD) (Kathmann et al., 2006). This is an interesting finding
considering that δ-opioid receptors can form a complex with β- and γ-secretases thereby promoting the
processing of APP to Aβ (Teng et al., 2010). Finally, there is also some experimental evidence to
support CBD activity in other pathways such as the dopamine and GABA neurotransmitter systems
[reviewed in (Pertwee, 2004)].
It has also been shown that CBD can increase adult hippocampal neurogenesis (Wolf et al., 2010).
Interestingly, this effect is absent in CB1 knockout mice suggesting that the effect of CBD on
neurogenesis is mediated by an indirect activation of CB1 receptors, possibly via inhibition of AEA
metabolism/uptake (as discussed earlier). Supporting this finding is a recent in vitro study showing that
CBD increases proliferation of hippocampal progenitor cells in culture, which can be prevented by
antagonists for both CB1 and CB2 receptors or overexpression of FAAH (Campos et al., 2011). Further,
AD-specific pharmacological actions of CBD have been reported. These will be outlined in more detail
in the following sections (in particular, sections 3.1 and 3.2) where the therapeutic properties of CBD
in preclinical models for the disease are discussed (for full overview of pharmacological actions of
CBD see Table 2).

3. CBD: A new treatment option for Alzheimer’s disease – a preclinical perspective
As discussed in section 2.2, the molecular mechanisms in which CBD exerts its various effects are still
under debate with evidence suggesting that its actions are not confined to the receptors of the
endocannabinoid system. Importantly for this review, a number of studies provide evidence that CBD
exerts various properties including neuroprotection, anti-inflammatory and anti-oxidant effects, and is
able to modulate the function of the immune system [as reviewed in (Campbell and Gowran, 2007,
Pertwee, 2008, Izzo et al., 2009, Scuderi et al., 2009, Booz, 2011)]. This evidence will be outlined in
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the following sections in the context of in vitro (section 3.1) and in vivo models (section 3.2) relevant to
AD.

3.1 Effects of CBD on in vitro Alzheimer’s disease models
Tau pathology
CBD was reported to suppress the hyperphosphorylation of tau protein in Aβ-stimulated PC12 neuronal
cells in a dose-dependent manner. The CBD-induced suppression was associated with a reduction of
phosphorylated glycogen synthase kinase 3-β (p-GSK3-β), the active form of GSK3-β, a
multifunctional phosphorylating serine/threonine kinase (Esposito et al., 2006a). Importantly, active pGSK3-β is also known as tau protein kinase and is responsible for tau protein hyperphosphorylation
and NFT formation in brains of patients with AD (Sperber et al., 1995). GSK3-β activation also
induces Aβ overproduction because of its impact on APP processing (Phiel et al., 2003). Furthermore,
Aβ peptide induces GSK3-β phosphorylation in hippocampal and cortical neurons thereby disrupting
the Wnt signalling function (Garrido et al., 2002). Aβ–induced Wnt pathway disruptions are pivotal
events in the neuronal apoptosis characteristic of AD, involving p-GSK3-β upregulation and β-catenin
degradation (De Ferrari and Inestrosa, 2000). In line with this, β-catenin levels are decreased in brains
of AD patients (Satoh and Kuroda, 2000). These data suggest that CBD inhibits tau
hyperphosporylation by disrupting phosphorylation of GSK3-β and thereby rescues at least some
aspects of the Wnt signalling pathway. Importantly, pharmacological interventions that rescue Wnt
activity have been proposed as novel therapeutics for AD treatment in the past (Esposito et al., 2006a).
Amyloid β pathology
Direct modulatory effects of CBD on APP processing have only recently been evaluated in in vitro
studies. Transfected human neuroblastoma SHSY5YAPP+ cells exhibited significantly elevated fulllength APP expression compared to control neuronal cells (Scuderi et al., 2014). CBD counteracted this
elevation in a dose-dependent manner by inducing ubiquitination of APP without having any effect on
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control cells. The CBD effect on SHSY5YAPP+ cells was paralleled by a progressive reduction of Aβ
peptide expression in cell lysates and consequentially less apoptopic events (i.e. number of apoptopic
cell bodies and % neuron survival) in these cells (Scuderi et al., 2014). Importantly, the peroxisome
proliferator-activated receptor-γ (PPARγ) antagonist GW9662 blocked these effects of CBD whereas
the involvement of α-, β- and γ-secretases were ruled out. PPARs are ligand-activated transcription
factors that belong to the nuclear hormone receptor superfamily and include three isoforms (i.e. α, β/δ,
and γ). PPARs have been linked to inflammation, cell proliferation, and differentiation. Importantly,
PPARγ receptors are expressed at low levels under physiological conditions but rise in response to
some pathological situations including AD (Kitamura et al., 1999). In line with this, PPARγ activation
has been found to reduce APP expression (d'Abramo et al., 2005) and dramatically enhance clearance
of Aβ in vitro (Camacho et al., 2004). Thus, CBD may exert a beneficial effect on the amyloidogenic
pathway through a mechanism involving PPARγ. This presents a novel promising avenue to counteract
the progression of AD and would be in line with suggestions that regulating PPARγ activity may be
therapeutically effective for AD pathophysiology. Related to the impact CBD has on the amyloidogenic
pathway, other synthetic cannabinoids (i.e. the CB2 agonist JWH-015) have been found to increase the
phagocytosis of Aβ by mouse microglial cells (Ehrhart et al., 2005) and promote the removal of Aβ
from human frozen tissue sections at low doses (Tolon et al., 2009). Importantly, CB2 expression is
upregulated in glial cells under chronic neuroinflammatory conditions such as AD.
Aβ-induced toxicity
CBD dose-dependently alleviated various other effects of Aβ-induced toxicity in a cultured rat
pheocromocytoma PC12 cell model (Iuvone et al., 2004). CBD administration prior to Aβ treatment
improved cell survival, reduced lipid peroxidation and production of reactive oxygen species (ROS).
ROS have been found to play a role in Aβ-induced cell damage and death (Brera et al., 2000) The
phytocannabinoid also increased caspase 3 protein levels (used as a hallmark of apoptosis), DNA
fragmentation and intracellular calcium levels, which were elevated in Aβ-treated cells without CBD
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treatment. Importantly, caspases are essential mediators of many of the pathways involved in executing
the apoptopic programme following Aβ accumulation (Nicholson and Thornberry, 1997). Furthermore,
Aβ-induced DNA fragmentation, a hallmark of apoptosis, has previously been found in AD models
(Gschwind and Huber, 1995), and a rise in calcium levels has been suggested to be responsible for at
least some of the toxic effects of Aβ (Mattson, 2002). Finally, an Aβ-induced decrease in the procaspase 3/total caspase 3 ratio was counteracted by CBD, suggesting that CBD could exert a protective
role at the execution phase of apoptosis, as activation of procaspase 3 to caspase 3 normally serves as
the convergence point of different apoptotic signalling pathways (Iuvone et al 2004). The effects of
CBD appeared to be independent of CB1 receptors, as SR141716A treatment (a CB1 receptor
antagonist) did not modulate the CBD properties observed. The authors concluded that CBD exerts a
combination of neuroprotective, anti-oxidant, and anti-apoptotic effects against Aβ-induced toxicity.
In line with the above findings, stimulation of PC12 cells with Aβ caused a significant increase in
nitrite production and inducible nitric oxide synthase (iNOS) protein expression. iNOS and its
enzymatic product nitric oxide (NO) are among the most important neurotoxic effectors in AD. NO is
predominantly released by activated glial cells and may disrupt neurons thereby sustaining the proinflammatory conditions typical for AD (Cardenas et al., 2005). CBD inhibited these consequences of
Aβ toxicity dose-dependently. This neuroprotective effect of CBD was mediated by suppressing the
Aβ-induced increase in phosphorylation of p38 mitogen-associated protein kinase (p38 MAP kinase)
and activation of nuclear factor-ĸB activation (NF-ĸB) (Esposito et al., 2006b). The transcription factor
NF-ĸB is stimulated by stress-responsive protein kinases (e.g. p38 MAP kinase) and regulates the
expression of genes involved in cell differentiation, proliferation and apoptosis as well as oxidative and
inflammatory responses. Furthermore, NF-ĸB activation is required to induce iNOS protein
transcription in post-mortem AD brains (Haas et al., 2002).
A more recent study was not able to confirm the neuroprotective effects of CBD: CBD protected rat
PC12 peripheral neuronal cells and human SH-SY5Y cells against oxidative stress and lipid
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peroxidation induced by tert-butyl hydroperoxide but failed against Aβ1-40 fibril and aggregate-evoked
neurotoxicity (Harvey et al., 2012). This unexpected finding was probably due to the fact that the
previous studies incubated cells with non-fibrillar Aβ, whereas Harvey et al. utilised Aβ in its
preformed (fibrillar) state when incubating the neuronal cell lines. Thus the neuroprotective efficacy of
CBD appears dependent on Aβ fibril formation occurring during cell exposure, which implies either a
direct influence on fibril formation or interference with Aβ fibril uptake or processing. CBD was
neuroprotective against oxidative stress generated from tert-butyl hydroperoxide but not from Aβ
exposure as there are differences in the neurotoxicity profile caused by these two stressors. It is likely
that Aβ activates additional pathways in evoking cell death that are not surmountable via antioxidant
capacity alone whereas tert-butyl hydroperoxide will directly attack membrane lipids (Harvey et al.,
2012). Interestingly, AEA effectively protected neuronal cells against Aβ fibril and aggregate-evoked
neurotoxicity via a pathway unrelated to CB1 or CB2 receptor activation, although both neuronal cell
lines expressed CB1 receptors (low expression of CB2 only) (Harvey et al., 2012).
The same team went on to analyse the potential inhibition of native Aβ fibrils and oligomer formation
by CBD (and other cannabinoids, e.g. THC, JWH-015 and 2-AG). Human neuroblastoma SHSY5Y
cells were exposed to Aβ42 directly and cell viability was measured in the presence of CBD. SHSY5Y
cells were also exposed to microglia-conditioned media (BV-2 cells) activated with lipopolysaccharide
(LPS), albumin or Aβ42, after which TNF-α and nitrite production were evaluated following CBD
treatment (Janefjord et al., 2014). Aβ42 evoked a concentration-dependent loss of cell viability in
SHSY5Y cells but negligible TNF-α and nitrite production in BV-2 cells compared to LPS or albumin.
CBD protected against Aβ–induced cell viability loss directly as well as against LPS-activated BV-2
conditioned media viability loss. CBD also altered the morphology of Aβ fibrils and aggregates to
some extent (but to a lesser degree than other cannabinoids). However, there was no clear correlation
between changed morphology and neuroprotective actions. In line with the previous study outlining the
role of endocannabinoids in Aβ–relevant neuroprotection (Harvey et al., 2012), of all the other
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cannabinoids used, only the endocannabinoid 2-AG was found to provide significant and direct
neuroprotection against Aβ42 (Janefjord et al., 2014). The authors raised another interesting point: there
was a trend for cell viability levels to be improved in the CBD control group (i.e. without Aβ
pretreatment). This may point towards a cellular proliferative or mitochondrial stabilising effect of
CBD that could potentially offset the loss of viability induced by Aβ42.
Microglial function
A consistent pathology of AD is glial activation. Microglia are the resident macrophages of the brain
and play a major role in the active immune defense of the CNS against pathological events. When
membrane receptors of microglia are activated [e.g. by adenosine triphosphase (ATP), which is
released by dying cells], these glial cells migrate towards the site of injury and release e.g. proinflammatory cytokines and NO. In AD, microglia overstimulation may be responsible for the
inflammatory conditions typically found in patient brains and may result in neurodegeneration. Thus,
pharmacological

manipulation

of

microglia

activity

may

have

therapeutic

potential

for

neurodegenerative diseases in general and for AD in particular. However, microglia can have helpful
and harmful phenotpyes. Thus, it is very likely that a balanced immune-modulation is required for AD
therapy, as immune activation of microglia can clear plaques whereas chronic neuroinflammation can
cause neuronal death/dysfunction (Krause and Muller, 2010).
Walter and colleagues (2003) discovered that microglia express both CB1 and CB2 receptors.
Furthermore, stimulation of microglia with ATP in vitro increased the production of 2-AG and
triggered glial cell migration (Walter et al., 2003). Importantly, CBD prevented the 2-AG-induced
migration of microglial cells possibly via antagonism at CB2 and ‘abnormal CBD’ receptors [for the
latter see (Jarai et al., 1999)]. In line with this, another study found that several synthetic cannabinoids
blocked Aβ-induced activation of cultured microglia, which was assessed by microglial cell activity,
morphology, and TNF-α release (Ramirez et al., 2005). This effect was evident for HU-210 but also for
cannabinoids with CB2 selectivity (i.e. JWH-133) and no anti-oxidant properties (i.e. WIN 55,212-2).
21

Interestingly, JWH-133 was as effective as the mixed CB1/CB2 agonist WIN 55,212-2 in the inhibition
of microglia activation (Ramirez et al., 2005). A more recent study confirmed and expanded on these
findings, as not only WIN 55,212-2 and JWH-133 but also CBD dose-dependently decreased the ATPinduced increase in intracellular calcium in cultured N13 microglial cells and in rat primary microglia.
The properties of CBD in the N13 cell model were independent of its actions on CB1 and CB2 receptors
whereas those properties could be blocked by CB2 antagonism in the primary microglia model (MartinMoreno et al., 2011). The research team also investigated a potential involvement of adenosine
receptors and found that an agonist of the adenosine A2A receptor (i.e. CGS-21680) mimicked the
actions of CBD. More importantly, an A2A antagonist (i.e. ZM241,385) suppressed the effects of CBD
in both the N13 and the primary microglial cell models (Martin-Moreno et al., 2011). Finally, CBD
promoted primary microglial migration, a phenomenon which could be stopped by CB1 and CB2
receptor antagonism (i.e. SR141716 and SR144528 respectively).
Acetylcholine
It is important to realise that Aβ not only induces neurodegeneration but also has downstream effects
including the severe disruption of several neurotransmitter systems. For example, cholinergic neurons
are lost in brain areas relevant for memory processing (i.e. amygdala, hippocampus and frontal cortex)
and this deterioration is accompanied by a decrease in acetylcholine (ACh), which plays a crucial role
in cortical development and activity and the modulation of cognition, learning and memory (Schliebs
and Arendt, 2011). So far, no research has been carried out to determine the effects of CBD on the
cholinergic system and the ACh-releated changes in AD. However, it is interesting to note that the
phytocannabinoid THC was found to completely inhibit the enzyme actylcholinesterase and its
aggregating effect on Aβ in vitro (and does so more effectively than currently approved AD
interventions such as donepezil and tacrine) (Eubanks et al., 2006).
Glutamate
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Aβ can also cause long-term disruptions to glutamatergic neurotransmission (Schliebs and Arendt,
2011). Under normal physiological conditions, glutamate activates NMDA receptors, allowing calcium
ions (Ca2+) to flow into the post-synaptic neuron. This triggers a signalling cascade that produces
synaptic plasticity including long-term potentiation (LTP), thereby facilitating higher order processes
such as learning and memory (Parsons et al., 2013). In AD, NMDA receptors are overstimulated by the
presence of excess glutamate, leading to sustained Ca2+ influx. This prolonged Ca2+ overload increases
the production of NO, inhibiting mitochondrial activity and depleting intracellular ATP levels
(Takeuchi, 2010). The loss of energy results in impaired dendritic and axonal transport, and neuronal
function, generating an excitotoxic state and eventually neurodegeneration. In this context, it is
important to remember that CBD has been shown to reduce glutamate-, NMDA-, AMPA-, and kainateinduced toxicity in rat cortical neurones (Hampson et al., 1998). However, the direct effect of CBD on
the glutamatergic system in an AD-relevant context has not been investigated yet.

3.2 Effects of CBD on in vivo Alzheimer’s disease models
There is a body of literature available evaluating the therapeutic-like effects of THC and synthetic
cannabinoids on AD-relevant behaviours and brain pathology [e.g. (Ramirez et al., 2005, Aso et al.,
2013)]. The available in vivo evidence for the therapeutic properties of CBD in AD is much sparser.
Pure CBD was found to be inactive in cognitive domains of healthy rhesus monkeys and mice [e.g.
(Lichtman et al., 1995, Winsauer et al., 1999, Long et al., 2010)] although there is also limited evidence
that CBD i) facilitates extinction of a contextual fear memory in rats (Bitencourt et al., 2008) and ii)
blocks reconsolidation of aversive memories in rodents (Stern et al., 2012). Furthermore, work utilising
cannabis plant extract either high in CBD or THC revealed that acute treatment with CBD-rich extracts
did not impact the working memory of healthy rats in a delayed-matching-to-place task in the water
maze whereas THC-rich extracts impaired cognitive performance (Fadda et al., 2004). Interestingly,
CBD-rich extracts given concomitantly with THC-rich extracts did not block the memory-impairing
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(and catalepsy-inducing) effects of THC. It has been suggested that a >10-fold higher dose of CBD
over THC is necessary to effectively antagonise THC-mediated behavioural deficits [(Fadda et al.,
2004) – see also (Zuardi and Karniol, 1983)] (for further details on CBD-THC combination
treatments/effects see section 5.1).
Mouse models developing AD-relevant phenotypes
The following in vivo findings were not obtained in AD models but may be relevant to some of the
AD-related pathological and behavioural characteristics. In a mouse model for chronic liver disease,
CBD had therapeutic effects on hepatic encephalopathy [i.e normalising increased TNF-α receptor 1
gene and decreased brain-derived neurotrophic factor (BDNF) expression] and improved cognitive
functioning, which is impaired in mouse models for chronic liver disease (Magen et al., 2009). The
majority of CBD effects were blocked by pharmacological antagonism at A2A receptors. A follow-up
study by the same research team also discovered an involvement of 5-HT1A receptor activation in the
beneficial properties of CBD treatment in this model (Magen et al., 2010). However, CBD-induced
BDNF expression changes were not mediated by either receptor suggesting the involvement of yet to
be discovered pathways.
Iron content in brain appears positively correlated with poorer cognitive performance of AD patients
(Ding et al., 2009). Furthermore, iron-induced memory impairments are associated with increased
oxidative stress markers in the brain (de Lima et al., 2005). Thus, iron-induced cognitive deficits might
be linked to oxidative damage and the anti-oxidant properties of CBD might be beneficial in this
context. Indeed, high dose acute CBD as well as subchronic CBD treatment recovered the object
recognition memory performance of iron-treated rats without affecting cognition of control rats
(Fagherazzi et al., 2011).
Pharmacological rodent models for Alzheimer’s disease
Manipulations to the endocannabinoid system: AD-relevant experimental strategies were implemented
for the first time when Mazzola and coworkers found that the amnesic effects of Aβ25-35 and Aβ42
24

(measured in mice using the step-through passive avoidance test) could be blocked by co-treatment
with the CB1 antagonist SR141716A (Mazzola et al., 2003). Another study using pharmacological
rodent models for AD evaluated changes to the endocannabiniod system after rats had been exposed to
cortical Aβ42 administration. Aβ42 enhanced hippocampal 2-AG (but not AEA) levels concomitant with
the appearance of markers of neuronal damage, increased CB2 (but not CB1) protein expression, and
induced cognitive deficits in the passive avoidance task. Inhibition of endocannabinoid cellular
reuptake reversed hippocampal damage and loss of memory retention (but only when given early after
Aβ42 administration) (van der Stelt et al., 2006). These data suggested for the first time that early
modifications to the endocannabinoid system might protect against Aβ neurotoxicity and its
consequences. Indeed, detrimental effects of bilateral injection of Aβ40 fibrils into the hippocampal
CA1 area of rats on spatial memory and neuroinflammation (e.g. microglia and astrocyte activation, IL1β expression and Aβ clearance) were reversed by subchronic treatment with MDA7, a selective CB2
receptor agonist. Furthermore, Aβ40 injections were accompanied by increased hippocampal CB2
expression (Wu et al., 2013).
CBD treatment: Most relevant to this review are studies testing CBD in pharmacological models for
AD. When mice were inoculated with Aβ42 in the hippocampus and co-treated with CBD (i.p. route),
CBD dose-dependently suppressed Aβ-induced increases in glial fibrillary acidic protein (GFAP)
mRNA and protein expression (i.e. a marker of activated astrocytes) and reduced Aβ-induced iNOS
and IL-1β protein expression, and the related NO and IL-1β release (Esposito et al., 2007). IL-1β is
involved in events related to neurodegeneration including synthesis and processing of APP and
astrocyte activation, which is followed by iNOS over-expression and excessive production of NO.
Thus, CBD was effective in counteracting aspects of the neuroinflammatory response to Aβ challenge
and a CB2-related mechanism was put forward by the authors (Esposito et al., 2007). Interestingly, CB2
overexpression has been detected in an Aβ-induced rat model of reactive gliosis (van der Stelt et al.,
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2006), and CB2 affects reactive gliosis at neuroinflammatory sites, thereby playing a role in the
progression of brain damage (Walter and Stella, 2004).
Confirming the cognition-rescuing and anti-inflammatory effects of CBD reported by Esposito and coworkers is another study that determined the effects of chronic CBD treatment on these domains in
mice injected i.v.c. with fibrillar Aβ. CBD treatment reversed the compromising effects of Aβ on
Morris water maze learning (no data were available for the memory consolidation and retention of
these mice). CBD did not alter the Aβ–induced increase in TNF-α mRNA expression but decreased
levels of IL-6 (Martin-Moreno et al., 2011).
Transgenic mouse models for Alzheimer’s disease
The endocannabinoid system in AD transgenic mice: A limited number of studies paid close attention
to the expression profile of the cannabinoid receptors CB1 and CB2 in the context of AD. CB1
immunoreactivity was reduced in hippocampal regions (i.e. CA1 and CA2/3) of APPxPS1 mice, an
established transgenic mouse model for familial AD (Kalifa et al., 2011). This CB1 phenotype was
associated with astroglial proliferation and elevated expression of the iNOS and TNF-α suggesting that
lower CB1 expression levels in AD transgenic mice may diminish anti-inflammatory processes thereby
exacerbating AD-associated pathology. Another study found no changes to CB2 protein expression in
APP transgenic mice (Martin-Moreno et al., 2012). Finally, a triple AD transgenic mouse model (i.e
harboring PS1M146V, APPSwe, and TauP301L transgenes), exhibited increased CB1 expression in prefrontal
cortex, dorsal hippocampus, and basolateral amygdala complex, whereas expression levels were lower
compared to control mice in the ventral hippocampus from 6 months of age onwards (Bedse et al.,
2014).
Expanding on these earlier findings, APP23 transgenic mice were crossed with CB1 knockout mice to
study the impact of CB1 deficiency on AD pathology (Stumm et al., 2013). Most double mutant mice
died before the onset of AD pathology but surviving mice exhibited reduced levels of APP and its
fragments which were accompanied by a reduced plaque load and less inflammation. These findings
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point to a regulatory role of CB1 on APP processing. Compared to APP23 transgenic and CB1 knockout
mice, double mutant APP23/CB1 mice showed even more impaired learning and memory deficits in the
Morris water maze.
Manipulations to the endocannabinoid system: Moving on from these expression studies using AD
transgenic mice, a small number of research teams have evaluated the effects of cannabinoids other
than CBD on AD-relevant behaviours and brain pathology of established transgenic mouse models for
the disease. Martin-Moreno and co-workers studied the effects of prolonged oral administration of
WIN 55,212-2 or JWH-133 on cognition and inflammation in APP transgenic mice (i.e. for 4 months
starting at 7 months, prior to plaque pathology and cognitive deficits). The CB2 agonist JWH-133 (but
not WIN 55,212-2) prevented the development of object recognition memory impairments (MartinMoreno et al., 2012). Furthermore, glucose uptake in the brain (as measured by
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F-fluoro-

deoxyglucose (18FDG) uptake using PET), which is reduced in AD patients and correlated with
cognitive deficits, was reduced in AD transgenic mice. Finally, JWH-133 intervention fully reversed
this phenotype. Looking at neuroinflammation in this model system, JWH-133 normalised the density
of ionised calcium binding adaptor molecule 1 (Iba1)-positive microglia (increased in AD transgenic
mice) and both JWH-133 and WIN 55,212-2 reduced the enhancement of COX-2 protein levels and
TNF-α mRNA expression (both increased in AD patients and AD transgenic mouse models).
Futhermore, the synthetic cannabinoids were able to reduce the enhanced levels of Aβ 40 and of the
more amyloidogenic Aβ42 in APP mice, probably by enhancement of Aβ clearance through blood-brain
or CSF-barrier (Martin-Moreno et al., 2012). Finally, WIN 55,212-2 (but not JWH-133) prevented
reductions to p-GSK3-β in AD transgenic mice.
A recent study confirmed most of these findings when treating APPxPS1 mice with JWH-133 at the
pre-symptomatic stage (Aso et al., 2013). JWH-133: i) improved cognitive performance in the novel
object recognition test and the active avoidance task; ii) decreased microglial reactivity and reduced
expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ; iii) reduced the expression of
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active p38 and stress-activated protein kinase/c-Jun NH(2)-terminal kinase (SAPK/JNK); iv) increased
the expression of inactive GSK3β and lowered tau hyperphosphorylation; v) enhanced the expression
of superoxide dismutase 1 (SOD1) and SOD2 around plaques; but, vi) did not alter Aβ production.
Inconsistencies between these two studies (e.g. effects of JWH-133 on Aβ pathology and tau
hyperphosphorylation-relevant pathways, i.e. GSK3-β) were attributed to methodological differences in
regards to mouse model and treatment design chosen as well as specifics of biochemical analyses (Aso
et al., 2013). In this context, it is important to note that other cannabinoids have been found to lack any
therapeutic-like properties in AD transgenic mouse models [e.g. HU-210 in APP23/PS1 transgenic
mice: (Chen et al., 2010)].
CBD+THC combination treatment: Two studies so far have explored the potential of CBD+THC
combination compounds for AD therapy using AD transgenic mice (for further information on the
potential and issues around combination treatments using THC and CBD see section 5.1). In a first
experiment, Sativex® [mixture of a THC botanical extract (containing 67.1% THC, 0.3% CBD, 0.9%
cannabigerol, 0.9% cannabichromene, and 1.9% other phytocannabinoids) and a CBD botanical extract
(containing 64.8% CBD, 2.3% THC, 1.1% cannabigerol, 3.0% cannabichromene, and 1.5% other
phytocannabinoids) in a 1:1 proportion] was administered i.p., daily for a month to parkin-null, human
tau overexpressing (PK−/−/TauVLW) mice, which presents a model of complex frontotemporal dementia,
parkinsonism, and lower motor neuron disease. Sativex® treatment resulted in less abnormal stressrelated behaviours (e.g. overgrooming and stereotypies; cognition was not assessed except spontaneous
alternation version of the Y maze). Furthermore, the treatment reduced the metabolism of dopamine
(but not the level of dopamine itself) as well as gliosis (e.g. Iba1 levels), neuroinflammation (e.g.
GFAP levels), and iNOS levels in the cerebral cortex (Casarejos et al., 2013). Most relevant to AD is
the finding that Sativex® decreased the concentration of phosphorylated tau and Aβ plaques in cortex
and hippocampus and increased autophagy. The mechanism behind the effects of Sativex® has not
been evaluated yet.
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In a second study, botanical extracts high in THC (CBD content less than 0.5%) or high in CBD (THC
content less than 2.5%) as well as a combination thereof (CBD plus THC) were used to treat APPxPS1
transgenic mice at the early symptomatic phase (Aso et al., 2015). All three approaches preserved
object recognition memory of AD transgenic mice but THC had detrimental effects on cognition in
control mice. CBD+THC also reduced fear-associated learning impairments of APPxPS1 mice,
decreased soluble Aβ42 (but not Aβ40) levels in the cortex and changed plaque composition (but total
amyloid burden was unchanged). All cannabinoids reduced astrogliosis (decreased GFAP staining) but
only CBD+THC reduced microgliosis (i.e. decreased Iba1 staining). CBD+THC was also most
effective in reducing inflammation and modifying neuroinflammatory responses in APPxPS1 mice
[mRNA expression levels; for details see (Aso et al., 2015)]. Interestingly, the redox protein
thioredoxin 2 and the signaling protein Wnt16 were identified as significant substrates for the
CBD+THC-induced effects in AD transgenic mice. Thioredoxin 2 is a key component of the
mitochondrial antioxidant system that is responsible for the clearance of reactive intermediates and
repairs proteins with oxidative damage. The Wnt gene family encodes secreted signaling proteins,
which have been implicated in several developmental processes, including axon guidance during
development and in response to traumatic injury. Moreover, activation of the Wnt signaling pathway
prevents Aβ-induced neurotoxicity in vitro.
Pure CBD treatment: Our team has expanded on the aforementioned studies evaluating the potential
role of CB2 and CBD+THC combinations in AD therapy by focusing on CBD effects in AD transgenic
mouse models. We have run two studies exposing AD transgenic mice and control literemates to
chronic CBD (or vehicle) treatment, both to test for remedial as well as preventative properties of CBD
for AD therapy. In the remedial arm of this study, we treated double transgenic APPswe/PS1∆E9
(APPxPS1) chronically with CBD (daily i.p. injections) after the development of cognitive deficits and
Aβ pathology. CBD rescued social recognition memory and reversed object recognition deficits of
male APPxPS1 transgenic mice. These effects were specific for recognition memory as CBD had no
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impact on fear-associated memory or anxiety behaviours (Cheng et al., 2014a). Impairments in object
recognition have been linked to dysregulation of the glutamatergic system (Nilsson et al., 2007) and
CBD has been found to augment the effects of a NMDA receptor antagonist in humans (Hallak et al.,
2011). Furthermore, CBD protects against glutamate neurotoxicity (Hampson et al 1998) and
memantine, another NMDA receptor antagonist improved object recognition in another transgenic AD
mouse model (Scholtzova et al., 2008). So CBD may improve recognition memory via the
glutamatergic pathway.
For the preventative research strategy, we treated APPxPS1 mice with CBD or vehicle using a daily
voluntary oral administration scheme for 8 months beginning at 2.5 months of age when AD-like
pathophysiology is still sparse. Long-term oral CBD treatment prevented the development of social
recognition deficit in male APPxPS1 mice (Cheng et al., 2014b). The beneficial effect of CBD on
social recognition memory was not associated with a direct effect on Aβ levels. Insoluble and soluble
levels of Aβ40 and Aβ42 were no different between vehicle and CBD-treated APPxPS1 mice in cortex
and hippocampus. Levels of oxidation were not significantly altered in APPxPS1 mice in comparison
to their age-matched WT littermates, nor did we detect changes in the level of lipid oxidation in the
cortex of CBD-treated animals, despite its known antioxidant properties. It is possible that brains were
collected at an age (i.e. around 10 months of age), where nucleic acid oxidation differences between
APPxPS1 and control mice are not evident anymore (normally observed at 3- 5 months of age).
Although not significant, the data obtained based on the administration of one CBD dose only (i.e. 20
mg/kg) suggested that CBD might have a beneficial effect on cytokine levels, in particular TNF-α,
which would be in line with earlier findings discussed above [e.g. (Martin-Moreno et al., 2011)].
The study also revealed a complex relationship between CBD treatment, AD genotype, and brain levels
of cholesterol and phytosterols. These findings will be followed up in future work. This is important as
disturbances in brain cholesterol metabolism are associated with the major pathological features of AD
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(including Aβ and tau pathology) and dietary phytosterols can either interfere with critical functional
processes in AD or decrease amyloidogenic processing.

4. The endocanabinoid system and cannabinoid therapy in Alzheimer’s disease patients
To date there have been no clinical trials evaluating the therapeutic potential of CBD for AD. This is
probably due to the limited number of preclinical research studies investigating the effects of CBD in
AD thus far. However, two clinical trials testing CBD have been carried out, which have some
relevance for AD. In 2009, an interventional study explored the value of CBD in treating cognitive
dysfunction in schizophrenia (ClinicalTrials.gov identifier NCT00588731). The study was based on a
six-week, randomized, placebo-controlled, fixed dose trial comparing CBD with placebo added to a
stable dose of antipsychotic medications in patients diagnosed with schizophrenia. The second
interventionial study (ClinicalTrials.gov identifier NCT01502046) started in 2011 and was a double
blind, randomised, cross over, placebo-controlled phase 2 clinical trial to assess the neuroprotective
properties of CBD, THC, and Sativex in Huntington’s disease patients. Unfortunately, it was not
possible to obtain any information from the www.ClinicalTrials.gov website or from the lead
investigators about the effects of CBD effects on cognition or neuroprotection in humans. Nevertheless,
a few studies evaluated the role of the endocananbinoid system in AD patients and the effectiveness of
cannabinoid treatment other than CBD in AD therapy and those findings will be outlined in the
following.

4.1 The endocannabinoid system in Alzheimer’s disease
Westlake and colleagues carried out autoradiographic studies using [3H]CP 55,940 binding (i.e.
synthetic CB1 and CB2 receptor agonist), in fresh frozen brain sections from normal aged humans,
Alzheimer's disease patients, and patients who died with other forms of cortical pathology (Westlake et
al., 1994). In AD brains, compared to normal brains, [3H]CP 55,940 binding was reduced in various
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regions of the hippocampus and the caudate nucleus. Less significant reductions were detected in the
substantia nigra and the globus pallidus. Other neocortical and basal ganglia structures were not
different from control levels. Levels of mRNA expression did not differ between AD and control
brains, but there were regionally discrete losses of the intensely expressing cells in the hippocampus. It
is important to note that the reductions in binding did not correlate with or localise to areas showing
histopathology (i.e. overall tissue quality or stainings for neuritic plaques and NFTs). Furthermore,
reduced [3H]CP 55,940 binding was associated with increasing age and with other forms of cortical
pathology. Thus, reductions in CB1/CB2 receptor expression appeared related to generalised aging
and/or disease process and were not selectively associated with AD.
These findings could not be replicated by follow up investigations. For example, Ramirez and
coworkers detected CB1 and CB2 receptor expression together with markers of microglia activation in
senile plaques in AD patients and that CB1-positive neurons were greatly reduced in areas of microglia
activation (no change to CB2 expression) (Ramirez et al., 2005). In line with this, immunoblotting for
CB1 receptors in postmortem cortical brain tissues (Brodmann area 10) from a cohort of
neuropathologically confirmed AD patients and age-matched controls revealed reduced CB1 expression
in AD brains, which was consistent with the loss of pyramidal cortical neurons in which these receptors
are substantially expressed. A correlation between reduced CB1 expression and hypophagia was found,
supporting the idea of a potential use of receptor agonists or cannabis sativa-derived cannabinoids in
the management of AD-associated eating disorders (Solas et al., 2013).
Another study analysed the expression of not only CB1 and CB2 receptors and also of FAAH in
hippocampus and entorhinal cortex sections from postmortem brains of AD patients using
immunohistochemistry (Benito et al., 2003). FAAH expression was increased in neuritic plaqueassociated astrocytes whereas CB2 receptors were abundantly and selectively overexpressed in
activated microglia. Supporting this finding is another study reporting elevated levels of CB2 receptors
in postmortem cortical brain tissues of AD patients. The elevated expression did not correlate with
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cognitive status but two relevant AD markers, i.e. Aβ42 levels and and senile plaque manifestation
(Solas et al., 2013). It can be postulated that CB2 receptors might be modulators of the inflammatory
response associated with neurodegenerative processes and therefore presents a possible target for new
therapeutic approaches. Importantly, the expression of CB1 receptors was not affected by AD. In line
with Benito et al (2003) is a more recent study applying semi-quantitative (immunoblotting) and
quantitative (radioligand binding) assessments to confirm that CB1 receptor levels were unchanged in
AD in several brain regions (i.e. frontal cortex, anterior cingulate gyrus, hippocampus, and caudate
nucleus) (Lee et al., 2010). Finally, comparative protein profiling and quantitative morphometry
showed that overall CB1 protein levels in the hippocampi of AD patients remained unchanged relative
to age-matched controls, and that CB1-positive presynapses engulfed Aβ-containing senile plaques
(Mulder et al., 2011). Lee and coworkers commented on the limitations of their study design regarding
neuroanatomical resolution (i.e. no subregion analyses were carried out), which did not allow the
detection of subtle CB1 expresssion changes in specific cytoarchitectural or neuroanatomical domains.
Furthermore, the functional status of CB1 receptors was not considered, which might be important, as
Ramirez and coworkers found elevated nitration of both CB1 and CB2 protein in AD brains (Ramirez et
al., 2005). It is interesting that a correlation was found between frontal cortical CB1 immunoreactivity
and cognitive scores (i.e. MMSE and CAMCOG) assessed within a year before death in the AD patient
group suggesting that CB1 receptors are intact in AD and may play a role in preserving cognitive
function (Lee et al., 2010). However, a more recent study using immunoblotting could not replicate this
finding when analysing correlations between cortical CB1 expression and the cognitive status (Mini
Mental State Examination score) of AD patients (Solas et al., 2013) (for overview on changes to the
endocannabinoid system in AD brain see Table 3).
The endocannabinoid system seems to be further involved in human AD pathology. In a case-control
study, the circulating levels of plasma endocannabinoids (eCBs) were analysed and the relationship
between eCBs and TNF-α was explored in elderly control subjects and AD patients. In comparison
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with controls, there were no significant differences in measured AEA or 2-AG concentrations in
plasma samples from patients with AD. Furthermore, endocannabinoid levels in the CSF were not
correlated to cognitive performance in healthy controls at risk for AD. In pooled plasma samples, an
inverse correlation was observed between plasma levels of 2-AG (but not AEA) and TNF-α, although
the levels of TNF-α were very low (Koppel et al., 2009). Further longitudinal studies will be required
to conclusively assess the impact of progressive AD pathology on circulating endocannabinoid levels.
Another study found increased hippocampal protein concentrations for the 2-AG synthesizing enzyme
DAGL-α/β in brain tissue of patients with definite Alzheimer’s (Braak stage VI). In particular, DAGLβ expression was found in microglia accumulating near senile plaques and apposing CB1-positive
presynapses. Furthermore, microglia, expressing 2-AG-degrading enzymes (i.e. ABHD6 and MGL)
began to surround senile plaques in brain tissue of patients with probable AD (Braak stage III) (Mulder
et al., 2011). Interestingly, ABHD6 expression ceased in NFT-bearing pyramidal cells, whereas
pyramidal cells containing hyperphosphorylated tau retained MGL expression (although at levels
significantly lower than in neurons lacking NFT pathology). Finally, it was revealed that MGL
recruitment to biological membranes was impaired in AD brains suggesting that disease progression
slows the termination of 2-AG signalling.
To conclude, the ‘endocannabinoid phenotype’ of AD brains appears to be complex and findings
appear at times contradictory and highly dependent on the methodologies applied (e.g. type of
polyclonal antibody, issue of cellular resolution in autoradiograpy studies, selection of mixed CB1/CB2
versus selective receptor agonists). However, summarising the diverse findings conservatively suggests
that alterations in the localisation, expression, and function of cannabinoid receptors occur in AD and
may play a role in its physiopathology, thereby providing a target for therapeutic interventions.

4.2 Effects of cannabinoids other than CBD on Alzheimer’s disease patients
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Volicier’s team was the first to evaluate the therapeutic effectiveness of cannabinoids in AD (Volicer et
al., 1997). Using a placebo-controlled crossover design, with each treatment period lasting six weeks,
effects of dronabinol (i.e. a pharmaceutical formulation of THC) on patients with a diagnosis of
probable AD who refused food were determined. AD patients on dronabinol treatment increased body
weight and showed decreased severity of disturbed behaviour. This effect persisted during the placebo
period in patients who received dronabinol first. Adverse reactions observed more commonly during
the dronabinol treatment than during placebo periods included euphoria, somnolence and tiredness, but
did not require discontinuation of therapy (Volicer et al., 1997).
A second study measured the effect of dronabinol on nocturnal motor activity, as nighttime agitation
occurs frequently in patients with dementia. Six late-stage AD patients were treated daily for two
weeks. Dronabinol led to a reduction in nocturnal motor activity and the patients also showed improved
Neuropsychiatric Inventory scores including for agitation, aberrant motor, and nighttime behaviours.
No side effects were observed for dronabinol treatment (Walther et al., 2006). These authors followed
up on their initial findings with a first randomized, controlled crossover trial of dronabinol for
nighttime agitation in two AD patients using actigraphy as the objective measure. Administration of
dronabinol led to reduced night time activity and strengthened circadian rhythms (Walther et al., 2011).
Finally, another case study investigated the effects of nabilone, a synthetic cannabinoid supposedly
mimicking the effects of THC, in the context of AD. Nabilone reduced the severity of agitation and
resistiveness of an AD patient during evening personal care with no emergent side effects. Previous
treatment attempts using donepezil and memantine had delivered disappointing results for this patient
(Passmore, 2008). No blinded or placebo studies have been conducted to date.

5. The future of CBD in Alzheimer’s disease therapy
To consider CBD as a novel therapeutic option for AD naturally requires an assessment of how well
humans tolerate CBD and what potential side effects might have to be expected. CBD has been
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described as being non-toxic and non-cataleptic, with no impact on food intake or physiological
parameters such as heart rate, blood pressure and body temperature and no role in psychomotor or
psychological functions. Chronic CBD use and high doses of up to 1,500 mg/day (orally) or 30 mg i.v.
are well tolerated in humans. However, some studies report that CBD can inhibit hepatic drug
metabolism, be immunosuppressive, induce lymphocyte apoptosis in vitro, and decrease fertilisation
capacity and the activity of p-glycoprotein and other drug transporters [reviewed in depth in
(Bergamaschi et al., 2011)]. Importantly, long-term safety studies are missing to this date and the effect
of CBD in particular in the elderly has not been assessed at all. Drug-drug interactions have not been
evaluated in any detail either. However, it is known that CBD has an inhibiting effect on CYP
isozymes, primarily CYP2C and CYP3A classes of isozymes. Thus, CBD could potentially impact on
antiepileptic medication, as e.g. valproate and clobazam are metabolised via these isozymes. In
conclusion, further studies are needed to clarify these potential in vitro and in vivo side effects before
CBD can be trialled clinically [for a detailed overview of CBD safety in vitro and in vivo, both for
rodents and humans, see (Bergamaschi et al., 2011): Tables 1 and 2; for side effects of CBD in vitro
and in vivo, for rodents, monkeys and humans see Tables 3 and 4].
It will also be necessary to work out the best possible administration route for CBD to achieve
clinically effective plasma and brain concentration routes. Some initial studies have been completed in
this regard using rodent models (Deiana et al., 2012) but recent focus has shifted to assessing different
delivery methods for cannabinoids in humans. CBD has been delivered orally in an oil-based capsule in
some human trials. But because of the low water solubility of CBD, oral cannabinoid administration
can result in slow and erratic absorption. Furthermore, and as discussed earlier, CBD is barely absorbed
after oral administration (and absorption rates can be highly variable): bioavailability from oral
delivery has been estimated to be as low as 6% due to significant first-pass metabolism in the liver
(Mechoulam et al., 2002, Devinsky et al., 2014). Smoking and intravenous administration of
cannabinoids both produce reliable and similar pharmacokinetic profiles. However, smoking carries
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toxic risks and loss of active drug by combustion. An alternate method is intrapulmonary
administration of cannabinoids via vaporisation, which is regarded as an effective mode of delivery
since it results in fast onset of action and high systemic bioavailability and avoids risks associated with
smoking and the formation of pyrolytic toxic compounds as a result of combustion (Solowij et al.,
2014). However, this delivery method is limited by the need for specialised equipment and patient
cooperation with the administration method (Devinsky et al., 2014). The combined CBD+THC product
Sativex® is administered as a oromucosal spray and appears to be safe and effective (Wade et al.,
2010). The bioavailability achieved by oralmucosal delivery appears to be similar to the oral route but
less variable. Finally, transdermal approaches have also been investigated, but due to CBD’s high
lipophilicity, special ethosomal delivery systems would be required to prevent drug accumulation in the
skin, which are impractical and costly (Lodzki et al., 2003, Devinsky et al., 2014).

5.1 CBD+THC combination treatment strategy
It would be beyond the focus of this review to discuss the potential of combined CBD+THC treatment
for AD therapy although recent evidence suggests that such a combination therapy might provide the
‘best’ AD pathology counteracting properties of cannabinoids without the known detrimental effects of
pure THC treatment (i.e. by blocking those effects via CBD co-treatment). However, the nature of the
interactive relationship between THC and CBD appears very complex and the evidence provided in the
literature to date is inconclusive if not contradictory [i.e. CBD blocking and/or facilitiating THC
effects; e.g. (Karniol et al., 1974, Varvel et al., 2006, Klein et al., 2011); comprehensively reviewed in
(McPartland et al., 2015)]. Reviewing this growing body of literature, it is important to pay close
attention to the timing of CBD versus THC intake, the CBD:THC ratio and the route of administration.
CBD can increase the potency of THC by pharmacokinetic interaction if CBD is administrated before
THC, or a pharmacodynamic interaction may occur when both cannabinoids are taken together, mainly
at a high dose ratio of CBD:THC [reviewed in (Bergamaschi et al., 2011)].
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It should be emphasized here that THC alone increases heart rate and change blood pressure, which
may have serious consequences in people with heart disease (Jones, 2002). Furthermore, THC impacts
on the risk to develop psychosis, although this effect is predominantly seen after long-term adolescent
THC/cannabis abuse and mostly in people with a genetic predisposition for psychosis (Arnold et al.,
2012). Long-term use of THC can also cause the development of cannabis dependency, a growing
problem in Western society. Finally, the negative effects of THC on cognitive abilities seem to be
reversible after abstinence, except in heavy cannabis users (Bolla et al., 2002). In this context it is
important to realise that there are no systematic data available determining the physiological and
psychological effects of long-term THC treatment in the elderly population to date [reviewed in
(Grotenhermen, 2007)].

6. Concluding remarks
AD is the most common form of dementia (i.e. around 70% of all dementia cases) and it is predicted
that AD will affect 1 in 85 people globally by 2050. For example, over 300,000 Australians are
currently affected by dementia at an estimated cost of $6.6 billion per annum, with the numbers
expected to grow to >700,000 by 2050. Considering the looming burden of AD, treatments that could
delay or even prevent the onset of AD would offer tremendous public health benefits. Unfortunately,
current therapeutic options are limited to modest symptomatic relief, without preventing disease
progression. The studies reviewed in this paper suggest that CBD could well provide symptomatic
relief and/or prevent disease progression for AD patients. However, a more systematic and in depth
characteristation of CBD in vivo, using established rodent models, is required to understand the full
consequendes of long-term CBD treatment and to analyse potential side effects of CBD in an aging
organism. Once those data are available, the translation of this preclinical work could be realized very
quickly as CBD is readily available and appears safe for human use. In fact, a number of countries (e.g.
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Canada and Germany) have already approved CBD-containing products for the treatment of pain and
inflammation in multiple sclerosis patients.
Such research would be very timely as it also falls within existing and developing federal regulations
concerning medical applications of cannabis and more importantly, extracts thereof, worldwide (e.g.
Australia, Canada, and Germany). Finally, understanding the pharmacology of CBD in more detail
including its long-term effects in the eldery will be relevant beyond research into AD therapy, as CBD
has been considered as a treatment option for e.g. Parkinson’s disease and schizophrenia as well.
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Involved in the majority of (D'Souza,
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2007,

(CB1)

CNS effects of cannabinoids Cabral et al., 2008)
including psychosis and in
immune functions

Cannabinoid receptor 2

Involved in immune function (Walter et al., 2003,

(CB2)

and

neuroinflammatory Ramirez

responses in CNS

et

al.,

2005, Pacher and
Mechoulam, 2011)

N-arachidonyl

glycine Abnormal

cannabinoid (McHugh

receptor or G-protein coupled receptor, activation by AEA 2010,
receptor 18 (GPR18)

et

al.,

McHugh,

and phytocannabinoids (e.g. 2012)
THC and CBD)

GPR55

Potential cannabinoid receptor, (Brown,
activated

by

both McHugh

endocannabinoids

and 2010,

phytocannabinoids

2007,

such

et

al.,

Henstridge,

as 2012)

THC and CBD
GPR119

Potential cannabinoid receptor, (Brown,
implicated in regulation of McHugh
food intake and body weight; 2010)
Activation by AEA

Table 1: Components of the endocannabinoid system (ECS)
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2007,
et

al.,

Pharmacological target

Effect

References

In vitro studies
Inhibition of caspase 3

Increased cell survival, decreased (Iuvone et al.,

(involved in the signalling

ROS

pathway for CBD)

peroxidation in PC12 cells exposed

production

and

lipid 2004)

to Aβ
Inhibition of

Inhibits

nitrite

production

and (Esposito et al.,

phosphorylated p38 MAP

iNOS protein expression in PC12 2006b)

kinase; activation of nuclear cells exposed to Aβ
factor-kB
Rescue of Wnt/β-catenin

Rescues Aβ-induced toxicity and (Esposito et al.,

pathway

inhibits

tau

protein 2006a)

hyperphosphorylation in PC12 cells
exposed to Aβ
NMDA, AMPA and kainate

Reduction

of

glutamate-induced (Hampson et al.,

receptors

toxicity in primary cortical neurons

Activation of PPAR-γ

Induced ubiquitination of APP and (Scuderi et al.,

1998)

decreased Aβ production in APP- 2014)
expressing human neuroblastoma
cells
In vivo studies
Glial pathways

Reduction in interleukin-1β, iNOS (Esposito et al.,
expression and subsequent NO 2007)
release in Aβ-injected mice

56

Microglia

Induced

microglial

migration, (Martin-Moreno

suppression of interleukin-6 and et al., 2011)
prevented spatial memory deficits
in Aβ-injected mice
Indirect activation of CB1

Increased adult neurogenesis in (Wolf et al.,

receptor

CB1 receptor deficient mice with no 2010)
effect on cognition in WT mice

Activation of PPAR-γ

Induced hippocampal neurogenesis (Esposito et al.,
and reduced reactive gliosis in Aβ- 2011)
injected rats

Inverse CB2 receptor

Antagonises CB2 receptor agonists (Thomas et al.,

agonism

in WT mice

2007)

Table 2: Pharmacological targets of CBD
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Component of ECS

AD-relevant effects

References

CB1 receptors

No differences were reported for

(Benito et al., 2003, Lee

receptor expression, distribution or

et al., 2010, Mulder et

availability in cortex or hippocampus

al., 2011, Ahmad et al.,

of AD patients

2014)

CB1 receptor expression in AD was

(Westlake et al., 1994)

comparable to normal ageing
CB1 receptors reported to be rduced in

(Ramirez et al., 2005,

cortical areas and neurons away from

Solas et al., 2013)

senile plaques
CB1 receptor expression was reported to

(Solas et al., 2013)

not correlate with any AD biomarkers
or cognitive deficits
Nitrosylated in AD brain allowing the

(Ramirez et al., 2005)

potential for impaired coupling of
receptors
CB2 receptors

CB2 receptor expression reported to

(Solas et al., 2013)

correlate with Aβ42 levels and plaque
deposition but not cognitive changes
CB2 receptor expression reported to be
abundantly and selectively
overexpressed in microglia
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(Benito et al., 2003)

Nitrosylated in AD brain allowing the

(Ramirez et al., 2005)

potential for impaired coupling of
receptors
FAAH

Significantly increased FAAH

(Benito et al., 2003,

concentration in neuritic plaque-

D'Addario et al., 2012)

associated glia and in peripheral blood
mononuclear cells of AD patients
No changes in FAAH protein content in

(Mulder et al., 2011,

hippocampal homogenates

Pascual et al., 2014)

Decreased FAAH activity in frontal

(Pascual et al., 2014)

cortex of AD patients, which is
mimicked by the addition of Aβ40
peptide to control brain samples
AEA

No differences reported for AEA

(Koppel et al., 2009)

plasma concentration in AD patients
compared to control subjects
Lower AEA concentration in AD brain

(Jung et al., 2012)

(midfrontal and temporal cortices)
compared to control and inversely
correlated with Aβ42 peptide and
severity of cognitive deficits
Increased degradation of AEA in AD
frontal cortex compared to controls
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(Pascual et al., 2014)

2-AG

No differences reported for 2-AG

(Koppel et al., 2009)

plasma concentration in AD patients
compared to control subjects
Altered 2-AG signalling during late
stages of AD due to combination of
impared MAGL recruitment and
increased DAGL concentration
Table 3: The endocannabinoid system and Alzheimer’s disease
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(Mulder et al., 2011)

